<i>Letter to the Editor:</i> Real-Life Experience of Long-Acting Cabotegravir–Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report-Reference-Cited by-同舟云学术

Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir–Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report

Published:2024-02-02 Issue: Volume: Page:
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Ciccullo Arturo¹^ORCID,Iannone Valentina²,Lombardi Francesca³,Borghetti Alberto³,Di Giambenedetto Simona²³

Affiliation:

1. Department of Medicine, Infectious Diseases Unit, San Salvatore Hospital, L'Aquila, Italy.

2. Catholic University of the Sacred Heart, Roma, Italy.

3. Department of Safety and Bioethics, UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.

Publisher

Mary Ann Liebert Inc

Link

https://www.liebertpub.com/doi/pdf/10.1089/aid.2023.0057

Reference4 articles.

1. Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities

2. Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

3. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study

4. Cabotegravir–rilpivirine treatment initiation in a nonvirologically suppressed patient

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People with HIV Who Are Virally Unsuppressed;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-03-27